Sotera Health's Promised Second-Half Sterigenics Uptick Faces Its First Real Test

Three months ago, Sotera Health's management told investors the second half of 2026 would bring a meaningful step up in its Sterigenics sterilization business, powered by new x-ray capacity, a large customer shifting work from in-house to outsourced, and friendlier facility shutdown timing. The third-quarter report, due before the open on November 3, is the first chance to see whether that promise shows up in the numbers. It is also the first full quarter under new CEO Alton Shader, who took over in late May.

Wall Street's expectations look notably cautious against that backdrop. Consensus calls for earnings of $0.24 per share, unchanged from a year ago and matching the second quarter, on revenue of about $319.4 million. That would be growth of just 2.6% from last year's $311.3 million and a slight sequential dip from the $321.4 million booked in the second quarter. For a company guiding full-year revenue growth of 5.25% to 6.75% in constant currency, a quarter in the low single digits needs explaining, and much of the explanation sits at Nordion. That unit pulled revenue forward into the second quarter at customers' request, pushing first-half sales above its typical 40% to 45% share of the year. Management framed this as timing rather than weaker demand, but it means Nordion will likely be a drag on the reported comparison this quarter.

The full-year guidance, narrowed upward last quarter, now sits at $0.95 to $1.01 in adjusted EPS and $1.236 billion to $1.254 billion in revenue. Consensus of $0.97 and roughly $1.24 billion lands in the lower half of both ranges, suggesting analysts are not yet giving the company credit for the high end. That matters because the raise was unusual: unlike last year, when a beat only lifted the bottom of the range, management pushed up the top as well, signaling better visibility. A quarter that keeps the high end intact, or nudges the midpoint higher again, would validate that confidence. Simply reaffirming the range while trimming the top would undercut it.

The operational evidence that matters most is at Sterigenics. The segment grew 7% in constant currency in the second quarter on only 2.7% volume growth, so investors should look for whether volume accelerates as x-ray revenue begins contributing and the insourcing conversion ramps. Pricing doing most of the work again would be acceptable, but the second-half story depends on volume. At Nelson Labs, the swing back to 5.4% growth and a sharp sequential margin rebound were encouraging, yet management cautioned that some of that business was transient and kept its full-year margin outlook in the low-to-mid 30s. Holding growth positive without a margin giveback would show the recovery has legs. Free cash flow and leverage, which reached 3.0x and the top of the 2x to 3x target last quarter, also deserve attention, especially with the second greenfield facility now moving forward and Shader still framing capital allocation priorities.

Sentiment has cooled noticeably despite the upbeat call. Bullish readings have slipped from nearly 30% ahead of the last report to barely positive now, and the shares have fallen 2.4% since then, modestly trailing the S&P 500. At $18.10, the stock remains above its 200-day moving average near $17.03 but sits in the lower half of its post-earnings range of $17.51 to $19.79, well short of a breakout. The market, in other words, has not paid up for the guidance raise.

That sets up a fairly clear test. If Sterigenics delivers the volume-driven acceleration management described and Nordion's softness reads as pure timing, the cautious bar leaves room for the improving narrative to regain traction. If the second-half uptick looks delayed or Nelson's rebound fades, the guidance raise will start to look like a high-water mark rather than a turning point.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.